The Journal of Antibiotics · 1999 · 14 citations · 6 references
MedicineOncologyPharmacologyCancer PharmacologyCell SignalingChemotherapyAntitumor AntibioticsGastric CancerGrowth Factor SignalingOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingGastric Cancer Pharmacotherapy
Thiazinotrienomycin B (TT-B), an ansamycin isolated from fermentation broths of Streptomyces sp. MJ672-m3, inhibited the growth in vitro of human stomach tumor SC-6 cells over 10 times more strongly than the growth of other human tumor cells, such as HeLa (cervix), T24 (bladder) and LX-1 (lung). The extent of growth inhibition by TT-B of SC-6, but not of LX-1 nor T24, was lowered in a competitive manner by raising serum concentrations in the culture medium. TT-B inhibited the cell cycle progression of SC-6 at an early stage of the progression from G0/G1 to S. The inhibition was again competitive with serum concentrations in the culture medium. No direct inhibition of DNA synthesis was observed at the concentration range which caused the cell cycle arrest. TT-B and anti-epidermal growth factor receptor (anti-EGFR) were antagonistic to each other in inhibiting the cell cycle progression of SC-6 from G0/G1 to S, suggesting that the two compounds share the same target, EGFR. The kinase activity of EGFR was little inhibited by TT-B in a cell-free system.
6
Kazuhiro Yoshida, Eikai Kyo, Tetsuhiro Tsujino et al. · Japanese Journal of Cancer Research · 1990 · 96 citations · Full text
Medicine, Cancer Biology, Oncology +13
Thiazinotrienomycins, New Ansamycin Group Antibiotics.
Nobuo Hosokawa, HIROSHI NAGANAWA, HIRONOBU IINUMA et al. · The Journal of Antibiotics · 1995 · 38 citations · Full text